1
|
Hao P, Zhang C, Ma H, Wang R. Enhanced tumor inhibiting effect of 131I-BDI-1-based radioimmunotherapy and cytosine deaminase gene therapy modulated by a radio-sensitive promoter in nude mice bearing bladder cancer. J Radiat Res 2023; 64:85-90. [PMID: 36418230 PMCID: PMC9855308 DOI: 10.1093/jrr/rrac075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 07/05/2022] [Indexed: 06/16/2023]
Abstract
Radioimmunotherapy (RIT) has great potential in cancer therapy. However, its efficacy in numerous tumors is restricted due to myelotoxicity, thereby limiting the dose of radionuclide. To increase tumor radiosensitivity, we incorporated the recombinant lentivirus into the EJ cells (bladder cancer [BC] cells), and examined the combined anti-tumor effects of RIT with 131I-BDI-1(131I-monoclonal antibody against human BC-1) and gene therapy (GT). The recombinant lentivirus was constructed and packed. The animal xenograft model was built and when the tumor reached about 0.5 cm in diameter, the mice were randomly separated into four groups: (1) RIT + GT: the xenografts were continuously incorporated with the recombinant lentivirus for two days. And 7.4 MBq 131I-BDI-1 was IV-injected, and 10 mg prodrug 5-fluorocytosine (FC) was IV-injected for 7 days, (2) RIT: same dose of 131I-BDI-1 as the previous group mice, (3) GT: same as the first group, except no 131I-BDI-1, and (4) Untreated. Compute tumor volumes in all groups. After 28 days the mice were euthanized and the tumors were extracted and weighed, and the inhibition rate was computed. The RIT + GT mice, followed by the RIT mice, exhibited markedly slower tumor growth, compared to the control mice. The tumor size was comparable between the GT and control mice. The tumor inhibition rates after 28 days of incubation were 42.85 ± 0.23%, 27.92 ± 0.21% and 0.57 ± 0.11% for the four groups, respectively. In conclusion, RIT, combined with GT, suppressed tumor development more effectively than RIT or GT alone. This data highlights the potent additive effect of radioimmune and gene therapeutic interventions against cancer.
Collapse
Affiliation(s)
- Pan Hao
- Corresponding author. Department of Nuclear Medicine, LuHe Hospital, Capital Medical University, No.82, Xinhuanan road, Tongzhou district, Beijing LuHe Hospital. Beijing, China, 101149, Phone: +13811079497, fax: +86 010-69543901-8000, : Chunli Zhang Author, Dept of Nuclear Medicine, Peking University First Hospital, 8 Xishiku Rd, Xicheng District, Beijing, China,100034, Phone: +86 13716887128, fax: +86 010-83572915, , , , ,
| | - Chunli Zhang
- Corresponding author. Department of Nuclear Medicine, LuHe Hospital, Capital Medical University, No.82, Xinhuanan road, Tongzhou district, Beijing LuHe Hospital. Beijing, China, 101149, Phone: +13811079497, fax: +86 010-69543901-8000, : Chunli Zhang Author, Dept of Nuclear Medicine, Peking University First Hospital, 8 Xishiku Rd, Xicheng District, Beijing, China,100034, Phone: +86 13716887128, fax: +86 010-83572915, , , , ,
| | - Huan Ma
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China
| | - Rongfu Wang
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China
| |
Collapse
|
2
|
Li L, Zhang CL, Kang L, Wang RF, Yan P, Zhao Q, Yin L, Guo FQ. Enhanced EJ Cell Killing of (125)I Radiation by Combining with Cytosine Deaminase Gene Therapy Regulated by Synthetic Radio-Responsive Promoter. Cancer Biother Radiopharm 2015; 30:342-8. [PMID: 26382009 PMCID: PMC4601673 DOI: 10.1089/cbr.2015.1862] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Aim: To investigate the enhancing effect of radionuclide therapy by the therapeutic gene placed under the control of radio-responsive promoter. Methods: The recombinant lentivirus E8-codA-GFP, including a synthetic radiation-sensitive promoter E8, cytosine deaminase (CD) gene, and green fluorescent protein gene, was constructed. The gene expression activated by 125I radiation was assessed by observation of green fluorescence. The ability of converting 5-fluorocytosine (5-FC) to 5-fluorourial (5-FU) by CD enzyme was assessed by high-performance liquid chromatography. The viability of the infected cells exposed to 125I in the presence of 5-FC was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and the infected cells exposed to 125I alone served as negative control and 5-FU as positive control. Results: The recombinant lentiviral vector was constructed successfully. On exposure of infected cells to 125I, green fluorescence can be observed and 5-FU can be detected. MTT assay showed that the survival rate for infected cells treated with 125I was lower compared with the 125I control group, but higher than the positive control group. Conclusion: The synthetic promoter E8 can induce the expression of downstream CD gene under 125I radiation, and the tumor killing effect of 125I can be enhanced by combining CD gene therapy with radiosensitive promoter.
Collapse
Affiliation(s)
- Ling Li
- 1 Department of Nuclear Medicine, Peking University First Hospital , Beijing, China
| | - Chun-li Zhang
- 1 Department of Nuclear Medicine, Peking University First Hospital , Beijing, China .,2 Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine , Wuxi, China
| | - Lei Kang
- 1 Department of Nuclear Medicine, Peking University First Hospital , Beijing, China
| | - Rong-Fu Wang
- 1 Department of Nuclear Medicine, Peking University First Hospital , Beijing, China
| | - Ping Yan
- 1 Department of Nuclear Medicine, Peking University First Hospital , Beijing, China
| | - Qian Zhao
- 1 Department of Nuclear Medicine, Peking University First Hospital , Beijing, China
| | - Lei Yin
- 1 Department of Nuclear Medicine, Peking University First Hospital , Beijing, China
| | - Feng-qin Guo
- 1 Department of Nuclear Medicine, Peking University First Hospital , Beijing, China
| |
Collapse
|
3
|
Zhen G, Cong-hui H, Lin H, Jian-jun Y, Wen-hao T, Gao-jun T. Preparation and in-vitro bioactivity of a novel superantigen conjugate targeting bladder carcinoma. J Pharm Pharmacol 2010. [DOI: 10.1211/jpp.61.07.0005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Abstract
Objectives
Superantigens have shown potent effects against bladder tumours by inducing Vβ-specific T-lymphocyte proliferation and massive cytokine release but therapeutic benefit is compromised by cytotoxicity towards non-malignant cells and hypotoxicity to major histocompability complex (MHC) II-negative tumour cells. We are therefore interested in a conjugate preparation of a monoclonal antibody (MAb)—superantigens conjugate for which these drawbacks would be resolved.
Methods
The Fab fragment of the anti-bladder carcinoma MAb BDI-1 was conjugated to one member of the staphylococcal enterotoxin A (SEA) superantigen using the chemical conjugating reagent, N-succinimidyl 3-(2-pyridyldithio) propionate.
Results
After HPLC purification through a Superdex-200 gel column, another peak with a molecular mass of 250 KDa was observed before Fab and SEA were eluted. Indirect immunocytochemical analysis and immunofluorescence tests showed that the cell membranes of most human bladder cancer cells were positively stained only by the conjugate, confirming the ability of the conjugate to target human bladder carcinoma. Peripheral blood mononuclear cell proliferation and cytokine release were similar with the conjugate and SEA. Cytotoxicity targeting in MHC II-negative bladder cancer cell lines, evaluated by flow cytometry, showed significant differences between the conjugate and SEA, whereas there was no difference in the Lovo colon cancer cell line.
Conclusions
These findings indicate the conjugate of SEA protein and BDI-1 Fab fragment was prepared successfully and targeted bladder carcinoma in vitro.
Collapse
Affiliation(s)
- Gong Zhen
- School of Clinical Medicine, Southeast University, Nanjing, PR China
- Department of Urology, Affiliated Xuzhou Hospital, School of Medicine, Southeast University, Xuzhou, PR China
- Laboratory of Molecular Imaging, School of Medicine, Southeast University, Nanjing, PR China
| | - Han Cong-hui
- School of Clinical Medicine, Southeast University, Nanjing, PR China
- Department of Urology, Affiliated Xuzhou Hospital, School of Medicine, Southeast University, Xuzhou, PR China
| | - Hao Lin
- Department of Urology, Affiliated Xuzhou Hospital, School of Medicine, Southeast University, Xuzhou, PR China
| | - Yang Jian-jun
- School of Clinical Medicine, Southeast University, Nanjing, PR China
| | - Tang Wen-hao
- School of Clinical Medicine, Southeast University, Nanjing, PR China
- Laboratory of Molecular Imaging, School of Medicine, Southeast University, Nanjing, PR China
| | - Teng Gao-jun
- School of Clinical Medicine, Southeast University, Nanjing, PR China
- Laboratory of Molecular Imaging, School of Medicine, Southeast University, Nanjing, PR China
| |
Collapse
|
4
|
Wang R, Zhang C, Yu L, Guo Y, Bai Y. Radiochemical synthesis and preliminary evaluation of anti-bladder cancer monoclonal antibody BDI-1 labeled with rhenium-188. J Labelled Comp Radiopharm 2001. [DOI: 10.1002/jlcr.470] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|